English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

1. Case Presentation Uterine carcinosarcoma (UCS), previously known as malignant mixed Mullerian tumor, is a very rare tumor of the female reproductive tract, composed of both high-grade sarcomatous and carcinomatous elements [1]. In the United States its incidence is 1-4 per 100,000 women, is more frequently find in black women and the median age at diagnosis is between 62-67 years old [1]. Risk factors for developing UCS include advanced age, obesity, nulliparity, exogenous estrogen use, pelvic radiation, and tamoxifen [2]. Due to its aggressive nature, up to 60% have an extrauterine disease at presentation [3]. A pelvic ultrasound is the first-line imaging study. The typical appearance is a heterogeneous solid intrauterine mass with an irregular shape, hypoechoic and septated cystic echotexture, an ill-defined boundary, possible expansion of the endometrial canal, and abundant blood flow signals [4, 5]. UCS has a worse prognosis compared to other high-risk uterine endometrial cancers, with reported five-year disease-specific survival rates of 59% for stage I/II disease, 22% for stage III disease, and 9% for stage IV disease, regardless of therapy [2].

A Rare and Aggressive Uterine Cancer: Carcinosarcoma